Novavax, Inc.

Novavax, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Novavax, Inc. has 164.82M shares outstanding.

As of June 30, 2026, Novavax, Inc. maintains a current ratio of 2.33, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -155.90, indicating conservative leverage, while an interest coverage ratio of -9.88 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -21.62, reflecting losses generated across the asset base. The company generates approximately 452,886.08 in revenue per employee across its workforce of 799.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.75 indicates how many times Novavax, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Novavax, Inc. recorded 2.11M in income tax expense. The company reported a pretax loss of -214.72M and -216.84M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Novavax, Inc.'s stock has gained approximately 14.20% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Novavax, Inc. generated 362.20M in revenue and converted that into -216.84M in net income, yielding earnings per share of -1.32. EBITDA reached -189.32M, while operating income came in at -119.29M.

As of June 30, 2026, Novavax, Inc. holds 629.64M in cash and equivalents against 260.24M in total debt, resulting in a net debt position of 87.56M. Total book value stands at -166.93M, with working capital of 385.59M providing operational flexibility.

Novavax, Inc. produced -32.30M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Novavax, Inc. posted a gross margin of 78.60, reflecting its pricing power and cost economics. The operating margin of -32.93 and net profit margin of -59.87 provide insight into operational efficiency.

Novavax, Inc.'s most recent stock split took place on May 10, 2019 with a 20:1 split ratio.